Personalized Peptide Therapies Will Drive Long-Term Biopharma Expansion
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
29 Jul 25
Updated
09 Aug 25
AnalystHighTarget's Fair Value
JP¥4,751.67
66.5% undervalued intrinsic discount09 Aug
JP¥1,590.50
1Y
-29.3%7D
-5.7%